Gain Therapeutics, Inc. GANX 深 滬
等待開盤 11-26 09:30:00 美东时间
2.92
+0.090
+3.18%
華盛通- 最 高2.93
- 今 開2.89
- 成交量 44.69万股
- 最 低 2.72
- 昨 收 2.83
- 總市值 1.06亿
- 52周最高 3.06
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 1.41
- 委 比 58.30%
- 總股本 3624.10万
- 歷史最高 17.93
- 量 比 0.48
- 振 幅 7.42%
- 歷史最低 0.89
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
Gain Therapeutics announced new preclinical data at Neuroscience 2025, showing GT-02287 reduces mitochondrial stress, improves neuronal survival, and enhances GCase trafficking to mitochondria, supporting its potential as a disease-modifying therapy for Parkinson’s disease. The findings are supported by three preclinical models: rat dopaminergic neurons, mouse PD models, and patient-derived fibroblasts with GBA1 mutation. GT-02287 decreased MIRO1...
11-20 12:00
Gain Therapeutics Q3 EPS $(0.15) Beats $(0.16) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 7.41 percent. This is a 11.76 percent increase over losses of $(0.17) per share from
11-12 20:14
Gain Therapeutics to Present at Neuroscience 2025
Gain Therapeutics announced a poster presentation at Neuroscience 2025 showcasing GT-02287, a small molecule allosteric modulator of glucocerebrosidase (GCase), targeting Parkinson's disease (PD) with or without GBA1 mutations. Preclinical data highlights disease-modifying effects, including restored enzymatic function, reduced pathology, and improved motor function in PD models. Phase 1 studies demonstrated favorable safety, tolerability, and ta...
10-30 11:00
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
Gain Therapeutics, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23 at The Hard Rock Hotel NYC. Gene Mack, President and CEO, will join a panel discussion on innovative approaches for neurogenerative diseases in clinical trials. Gain is a clinical-stage biotech company developing next-generation allosteric small molecule therapies for neurodegenerative diseases, rare genetic disorders, and oncology. Its lead candidate, GT-02...
10-16 11:00
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.
10-15 18:04
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Gain Therapeutics will host a virtual KOL event on October 14, 2025, at 4:00 p.m. EST, featuring experts Karl Kieburtz and Kenneth Marek. The event will discuss biomarkers, clinical endpoints, and data from GT-02287, a Phase 1b candidate for Parkinson’s disease. GT-02287 has shown favorable safety and trends of improvement in MDS-UPDRS scores. Preclinical data suggest potential disease-modifying effects. Registration for the event is available on...
10-09 11:00
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Gain Therapeutics Presents Phase 1b GT-02287 Data At International Congress Of Parkinson's Disease And Movement Disorders, Highlighting Safety, Tolerability, And Exploratory Findings In PD Patients With or Without GBA1 Mutation
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participantsPlasma exposures in patients within projected therapeutic range and comparable to exposures
10-06 20:20
